

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Martin Gall

SERIAL NUMBER: 10/671,107

EXAMINER: Laura Lynne Stockton

FILING DATE: September 25, 2003

ART UNIT: 1626

FOR: METHOD AND COMPOUNDS FOR TREATING GLAUCOMA VI

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed on the attached modified forms PTO-1449, as well as copies of the listed documents.

This Supplemental Information Disclosure Statement is being filed within three months of the mailing date of a Supplementary Partial European Search Report for EP 02 73 1958, mailed December 16, 2004 and before the mailing date of a first Office Action based on the merits in the above-identified case. Accordingly, no fee or certification is believed required. By the waiver of 37 CFR 1.98(a)(2)(i) a copy of the U.S. Patent A3 is not submitted.

It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and signs the enclosed form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

By submitting this Supplemental Information Disclosure Statement, the Applicants make no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by


APPLICANTS: Martin Gall
U.S.S.N.: 10/671,107

35 U.S.C. §102.

Notwithstanding any statements by the Applicants, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested.

Please charge any fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311, Reference No. 26448-515 CON.

Respectfully submitted,

 Reg No. 50,572

Ivor R. Elrifi, Reg. No. 39,529

Attorneys for Applicants

c/o MINTZ, LEVIN

Address all written correspondence to

Customer no.: 30623


Tel: (617) 542-6000

Fax: (617) 542-2241

Date: February 10, 2005

TRA 2005543v1

Please type a
plus sign (+)
in this box



PTO/SB (12-97)
Approved for use through 9/30/00. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Modified Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	10/671,107
	Filing Date	September 25, 2003
	First Named Inventor	Gall
	Group Art Unit	1626
	Examiner Name	Laura Lynne Stockton
	Attorney Docket Number	26448-515 CON

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
	*A3	5,866,595	02/02/99	Pershad Singh, et al.	514	369	

U.S. PUBLISHED APPLICATION DOCUMENTS							
Exam Initials	Cite No.	U.S. Published Application No.	Published Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS					
Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No
	B1	WO 90/11758	SANOFI	10/18/90	Abstract only
	B2	WO 02/096362 A2	ALTEON, INC.	12/05/02	

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C1	Namil et al. <i>Eur. J. Med. Chem.</i> , 30:973-981 (1995)
	C2	Supplementary Partial European Search Report for EP 02 73 1958, mailed December 16, 2004.

* By the waiver of 37 CFR 1.98(a)(2)(i) a copy of the U.S. Patents A3 is not submitted.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


02-11-05

JFW

Express Mail Label No.: EV 475171163 vs

Date of Deposit: February 10, 2005

Attorney Docket No.: 26448-515 CON



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Martin Gall

SERIAL NUMBER: 10/671,107

EXAMINER: Laura Lynne Stockton

FILING DATE: September 25, 2003

ART UNIT: 1626

FOR: METHOD AND COMPOUNDS FOR TREATING GLAUCOMA VI

Mail Stop Amendment

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Transmitted herewith for filing in the present application are the following documents:

1. Supplemental Information Disclosure Statement (2 pages), in duplicate;
2. Modified Form 1449/PTO (1 page), in duplicate;
3. Copies of Cited References: B1-2, C1-2; and
4. Return Postcard.

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 542-6000, Boston, Massachusetts.

The Commissioner is authorized to charge any fees that may be due, or to credit any overpayment, to the undersigned's account, Deposit Account No. 50-0311 Ref. No. 26448-515 CON. A duplicate copy of this transmittal letter is enclosed herewith.

Respectfully submitted,


 Matthew P. Reg. No. 59,572

Ivor R. Elrifi, Reg. No. 39,529

Attorneys for Applicants

c/o MINTZ, LEVIN

Address all written correspondence to

Customer no.: 30623

Tel: (617) 542-6000

Fax: (617) 542-2241

Date: February 10, 2005